Back to Search
Start Over
Venetoclax and hypomethylating agents yield high response rates and favourable transplant outcomes in patients with newly diagnosed acute myeloid leukaemia.
- Source :
- British Journal of Haematology; Mar2022, Vol. 196 Issue 6, pe71-e74, 4p
- Publication Year :
- 2022
-
Abstract
- The 1-year OS for HCT patients (21 patients) was 85% (95% CI 61-95%) compared to 41% (95% CI 16-65%) in non-HCT patients in cCR (14 patients). The 1-year LFS in patients who underwent HCT (21 patients) was 67% (95% CI 41-84%) I versus i 33% (95% CI 10-57%) in non-HCT patients in cCR (14 patients). [Extracted from the article]
- Subjects :
- ACUTE myeloid leukemia
CHRONIC leukemia
TREATMENT effectiveness
VENETOCLAX
Subjects
Details
- Language :
- English
- ISSN :
- 00071048
- Volume :
- 196
- Issue :
- 6
- Database :
- Complementary Index
- Journal :
- British Journal of Haematology
- Publication Type :
- Academic Journal
- Accession number :
- 155835519
- Full Text :
- https://doi.org/10.1111/bjh.17996